| 1 | Evolution of the newest diagnostic methods for COVID-19:a Chinese perspective显示文摘Coronavirus disease 2019(COVID-19)has continued to spread globally since late 2019,representing a formidable challenge to the world's healthcare systems,wreaking havoc,and spreading rapidly through human contact.With fever,fatigue,and a persistent dry cough being the hallmark symptoms,this disease threatened to destabilize the delicate balance of our global community.Rapid and accurate diagnosis of COVID-19 is a prerequisite for understanding the number of confirmed cases in the world or a region,and an important factor in epidemic assessment and the development of control measures.It also plays a crucial role in ensuring that patients receive the appropriate medical treatment,leading to optimal patient care.Reverse transcription-polymerase chain reaction(RT-PCR)technology is currently the most mature method for detecting viral nucleic acids,but it has many drawbacks.Meanwhile,a variety of COVID-19 detection methods,including molecular biological diagnostic,immunodiagnostic,imaging,and artificial intelligence methods have been developed and applied in clinical practice to meet diverse scenarios and needs.These methods can help clinicians diagnose and treat COVID-19 patients.This review describes the variety of such methods used in China,providing an important reference in the field of the clinical diagnosis of COVID-19. | Mingtao LIU Jiali LYU Xianhui ZHENG Zhiman LIANG Baoying LEI Huihuang CHEN Yiyin MAI Huimin HUANG Baoqing SUN | 2023 | Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)2023，24，6： | 0 |
| 2 | Cutting the root:the next generation of T cells engagers against cancer stem cells to overcome drug resistance in triple-negative breast cancer显示文摘Triple-negative breast cancer(TNBC)is the most difficult type of breast cancer to treat.TNBC is defined by the lack of expression of three receptors:estrogen receptor(ER);progesterone receptor(PR);and human epidermal growth factor receptor 2(HER2).Chemotherapy is currently first-line treatment for TNBC;however,due to the high heterogeneity of TNBC,most patients eventually develop chemotherapy resistance,which is associated with a poor prognosisl-2.Emerging immune checkpoint blockade(ICB)therapies have been shown to have promising therapeutic efficacy in treating solid tumors.A phase III clinical trial reported that the combination of ICB and chemotherapy lengthened progression-free survival in patients with metastatic PD-L1+TNBC3;however,most patients had primary resistance or acquired resistance to ICB.Thus,the intrinsic mechanisms underlying ICB resistance are still under investigation4. | Jiali Zhang Bin Liu Minchao Lyu Yourong Duan | 2023 | Cancer Biology & Medicine2023，20，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员